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Purpose. Determine patient-reported reasons for discontinuation with teriparatide. Methods. Patients taking teriparatide in
a multicenter, prospective, and observational study were given three questionnaires: baseline, follow-up questionnaire 1
(QF1, 2 to 6 months), and follow-up questionnaire 2 (QF2, 12 months). Discontinuation reported at QF1 and QF2 was
deﬁned as “early” and “late,” respectively, and remaining patients were considered persistent. Cochran-Armitage trend test
was used to identify factors associated with discontinuation. Results.S i d ee ﬀects, concern about improper use, injection
diﬃculties, and several patient-perceived physician issues were associated with early discontinuation. Low patient-perceived
importance of continuing treatment, side eﬀects, diﬃculty paying, and low patient-perceived physician knowledge were associated
with late discontinuation. The most common speciﬁc reasons selected for discontinuing treatment were “concerns about
treatment outweighing the beneﬁts” (n = 53) and “diﬃculty paying” (n = 47). Conclusions. Persistence with teriparatide is
dependent on managing side eﬀects, addressing ﬁnancial challenges, proper training, and obtaining support from the healthcare
provider.
1.Introduction
Osteoporosis underlies 1.5 million fractures per year in
the United States and imposes a tremendous ﬁnancial and
personal burden. It is characterized by low bone mass,
deterioration of bone tissue, and disruption of bony
architecture [1] ,a n dt h o u g hi tc a nb ei d e n t i ﬁ e da n d
successfully treated before fractures occur, adherence and
persistence with therapy are made diﬃcult by the need for
long-term treatment, the frequently asymptomatic nature
of the disease, and the fact that most patients taking treat-
ment do not perceive a clinical beneﬁt [2, 3]. Only 16%
to 50% of patients persist with therapy 12 months after
initiation [4–8], for patients receiving any of the following:
bisphosphonate, calcitonin, hormone replacement therapy
(HRT), or selective estrogen receptor modulator (SERM).
Poor persistence and adherence to osteoporosis therapy have
many adverse outcomes, including higher risk of fracture
[9–11].
Multiple therapies are currently available for osteoporo-
sis, but teriparatide (Forteo) is the only anabolic treatment
[12]. It is administered by the patient as a once-daily
subcutaneous injection (20µg) for up to 24 months [12].
The parenteral route of administration and higher cost of
teriparatide as compared to bisphosphonates might hinder
persistence with treatment. In addition, decreases in per-
sistence with teriparatide may represent a costly healthcare
expenditure with less than full protection against osteo-
porotic fracture, and persistence has important healthcare
economic implications. The primary objective of this study
was to identify patient-reported reasons for discontinuation
with teriparatide.2 Journal of Osteoporosis
2.MaterialsandMethods
Thisstudywasbasedonquestionnairescompletedatasubset
of sites participating in the direct analysis of nonvertebral
fractures in the community experience (DANCE) study [13],
a prospective, observational trial designed to examine the
eﬃcacy and tolerability of teriparatide as used in clinical
practice (ClinicalTrials.gov Identiﬁer: NCT01078805). The
multicenter, multispecialty study enrolled patients who
were treated with teriparatide and a protocol amendment
included questionnaires at baseline (QB), and 2 follow-up
questionnaires completed between Month 2 and Month 6
(QF1), and at Month 12 (QF2). The full questionnaires are
available in Figures1, 2, and 3 in Supplementary Material
(availableonlineatdoi:10.4061/2011/314970)andwerecon-
structedbasedontheﬁndingsfromastudybyBrodetal.[14]
(see below). The QB included items related to the patient’s
prior experience with self-injection of drugs, perception
of the severity of their osteoporosis, relationship with the
prescribingphysicianandhisorherstaﬀ,andconcernsabout
starting treatment. QF1 and QF2 included items related to
initial therapy training and ongoing support, early experi-
ence with teriparatide (including problems, adverse events,
and concerns), and whether the patient was currently taking
teriparatide. Patients who discontinued teriparatide between
baseline and Month 12 were asked to choose from among 6
possible reasons for discontinuation: “taken as long as physi-
cian prescribed,” “did not believe it was beneﬁcial,” “too hard
to follow all the steps necessary to use Forteo,” “problems
with injecting,” “concerns about treatment outweighed the
beneﬁts of treatment,” and “cost issues—diﬃculty paying for
it.” Discontinuation reported at QF1 and QF2 was deﬁned as
“early” and “late,” respectively. Patients who did not report
discontinuation were considered persistent. DANCE was an
observational study and thus all patient care was chosen and
conducted at the discretion of the participating study physi-
cian according to their clinical judgment and the local stan-
dardofmedicalcare.Thefulﬁllmentofteriparatideprescrip-
tions was at the discretion of the patient and could have been
mail-ordered or at a retail pharmacy. There was a customer
care program available for teriparatide patients concurrent
withthestudy(e.g.,seeQF1,no.6andQF2,no.3).However,
patients in DANCE were not required to use the customer
program and teriparatide patients could use the customer
program regardless of their involvement in DANCE.
2.1. Statistical Analyses. Summary statistics for baseline
demographic and medical characteristics were calculated for
all patients who had completed QB (n = 1267). Ordered cat-
egorical responses to the questions were scored numerically
as consecutive integers. Some questions with a conditional
sequentialresponsestructurewerecollapsedtosingleordinal
responses. For example, QF1 included “Have you experi-
enced any side eﬀects with the drug, Forteo.” Those patients
answering “yes” were asked to choose if the side eﬀects were
“mild,” “moderate,” or “severe.” The sequenceof answers was
converted to a single ordinal response: “severe side eﬀects,”
“moderate side eﬀects,” or “mild side eﬀects,” and “no side
eﬀects.” The method resulted in 17 items for QB, 24 items
Enrolled
Complete QB
Complete QF1
Complete QF2
Discontinued
treatment early
Discontinued
treatment late
n = 1379
n = 1267
Missing QB: n = 26
Incomplete QB: n = 86
n = 919
Missing QF1: n = 244
Incomplete QF1: n = 104
n = 655
Missing QF2: n = 160
Incomplete QF2: n = 40
n = 64
n = 68
Figure 1: Patient ﬂow chart.
for QF1, and 23 items for QF2. All tests of association
were evaluated by the asymptotic Cochran-Armitage trend
test. Tests were against the 2-sided alternative of a positive
or negative association at the 0.05 level. Analyses were
performed using SAS v9.1.3 for Windows (Cary, NC, USA).
Associations were tested between the following:
(i) survey items in QB and early treatment discontinua-
tion for those patients who fully completed QB and
QF1,
(ii) survey items in QF1 and early treatment discontinu-
ation for those patients who fully completed QB and
QF1,
(iii) survey items in QF2 and late treatment discontinua-
tion for those patients who fully completed QB, QF1,
and QF2.
3. Results and Discussion
Of the 1379 patients who enrolled, 1267 (92%) completed
QB in full (Figure 1). Of these, 919 had complete QB and
QF1 and were included in the analysis of early discontinu-
ation. There were 655 patients who also had complete QF2
and were included in the analysis of late discontinuation.
There were 404 patients (32% of 1267) who had one or more
missing follow-up survey(s) and 144 patients (11% of 1267)
who had one or more incomplete survey(s).
The characteristics of the cohort are described in Table 1.
The patients were mostly white females, but there was
notable representation of Hispanic patients. Nearly 1 in 3
had experienced at least one fragility fracture and about 4
out of 5 patients had a history of prior osteoporosis therapy.
The mean T-scores for the lumbar spine, femoral neck, and
total hip were somewhat higher than the range typically
considered osteoporotic (−2 . 5o rl o w e r ) .
Upon initiating teriparatide treatment, the patients had
relatively homogeneous attitudes about their disease, which
are summarized brieﬂy. Most patients (n = 746, 59%)
believed that their osteoporosis was “severe” or “very severe.”
Nearly all (n = 1217, 96%) believed that it was “very”
or “extremely important” to treat their osteoporosis. Many
patients (n = 1064, 84%) believed teriparatide would beJournal of Osteoporosis 3
Table 1: Demographics and baseline characteristics.
Variable N Value
Age in years, mean (SD) 1267 66.9 (11.4)
Female gender, n (%) 1267 1151 (90.8%)
Race, n (%) 1267
White 999 (78.9%)
African American 18 (1.4%)
Hispanic 230 (18.2%)
Other 20 (1.6%)
Education, n (%) 999
<High school 52 (5.2%)
High school 437 (43.7%)
College 414 (41.4%)
Graduate school 96 (9.6%)
History of ≥1f r a g i l i t y
fracture, n (%) 1226 388 (31.7%)
History of prior osteoporosis
therapy, n (%) 1254 1036 (82.6%)
Family history of
osteoporosis, n (%) 1176 481 (40.9%)
Family history of hip
fracture, n (%) 1177 232 (19.7%)
Lumbar spine T-score, mean
(SD) 1012 −2.34 (1.44)
Femoral neck T-score, mean
(SD) 976 −2.30 (0.97)
Total hip T-score, mean (SD) 777 −1.97 (1.00)
≥1 active medical condition,
n(%) 1255 1066 (84.9%)
Smoking, n(%) 1191 173 (14.5%)
Alcohol, n(%) 1172 289 (24.7%)
Caﬀeine, n(%) 1077 912 (84.7%)
“very” or “extremely eﬀective” at reducing the risk of future
fractures. Some patients (n = 374, 30%) were “very”
or “extremely concerned” about their ability to pay for
treatment. While only a few patients had experience using
self-injectable medications (n = 252, 20%), most (n = 789,
62%) were “very” or “extremely conﬁdent” in their ability
to inject themselves daily as instructed. Few patients thought
they would need help with the injections (n = 161, 13%).
Approximately 1 in 4 patients experienced side eﬀects (n =
234, 25%) with about half of these (n = 120) reporting
that the eﬀects were “moderate” or “severe.” When QF2 was
administered, 15% (96 of 655) of the remaining patients
reported having experienced side eﬀects.
Early discontinuation of teriparatide was reported by 64
(7% of 919) patients and an additional 68 (10% of 655)
patients reported late discontinuation. For both early and
late discontinuation, the most commonly selected reasons
were ﬁnancial diﬃculties and concerns about treatment
Table 2: Reasons given for discontinuation of teriparatide therapy
for those patients who reported early or late discontinuation.
Time of discontinuation early late
N (%) n (%)
Concerns about treatment
outweighed the beneﬁts 27 (42.2) 26 (38.2)
Cost issues—diﬃculty paying for it 19 (29.7) 28 (41.2)
Taken as long as physician
prescribed 11 (17.2) 10 (14.7)
Problems with injecting 8 (12.5) 3 (4.4)
Did not believe it was beneﬁcial 4 (6.3) 7 (10.3)
T o oh a r dt of o l l o wa l lt h es t e p s
necessary to use Forteo 3 (4.7) 0 (0.0)
Reason unspeciﬁed 2 (3.1) 2 (2.9)
aNote that some patients reported more than one reason. A total of 64
patients discontinued early and 68 discontinued late.
outweighing the beneﬁts (Table 2). No items in QB were sig-
niﬁcantly associated with early discontinuation. Associations
between items on survey QF1 and early discontinuation are
summarized in Figure 2. The discontinuation rate increased
with the reported severity of side eﬀects (P<. 001). For the
685 patients who reported no side eﬀects, fewer than 5%
discontinued. In contrast, 56% of the 27 patients reporting
severesideeﬀectsdiscontinued.Patientswhowereconcerned
that they were not taking the medication properly were
more likely to have discontinued early than if they had
little or no concerns about proper administration (P =
.01). Five diﬀerent items relating to diﬃculties with the
injection device were associated with early discontinuation
(all P<. 001); an example is shown in Figure 2.T h e r e
were also associations between early discontinuation and the
perception that the prescribing physician had a low level of
knowledge about teriparatide (P = .001), low enthusiasm
about treatment (P = .01), or a low level of conﬁdence in
the treatment (shown in Figure 2, P<. 001).
The late discontinuation rate was highest for patients
who “never” experienced pain at the injection site (Figure 3,
P = .002). Most patients had not used the patient assistance
telephoneline.However,2ofthe5patientswhodidnotthink
it was helpful discontinued. None of the 49 patients who
had called and found the assistance “very” or “extremely”
helpful had discontinued. Problems paying for medication
was also signiﬁcantly associated with late discontinuation
(P<. 001). Patients who thought it was “not at all” or “only
a little” important to continue treatment were more likely
to discontinue (P<. 001). Similar to early discontinuation,
patient-perceived physician knowledge (P = .01) and side
eﬀects (P<. 001) remained important factors with late
discontinuation.
The characteristics of patients initiating teriparatide
in this prospective observational study were consistent
with previous reports from administrative claims databases
[15, 16]. As wasseen in this study, most patients werefemale,4 Journal of Osteoporosis
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Figure 2: Responses to QF1 signiﬁcantly associated with early discontinuation (Cochran-Armitage trend test). Additional signiﬁcant
associations, which had trends similar to the questions shown, included: How diﬃcult has it been to: set the dose? inject yourself? clean and
store the pen? Other? Overall, how diﬃcult has it been to use Forteo as prescribed? Please think about the physician who is treating you with
Forteo: How enthusiastic is the physician about treatment with Forteo? How knowledgeable is the physician about treatment with Forteo?
olderthanage65,andhadpreviouslyusedothermedications
such as antiresorptives to treat their osteoporosis. Patients
commonly had a history of osteoporotic fracture. A strength
of the current study is that results from bone mineral density
measurements were available. The baseline mean T-score
was not in the range (i.e., −2.5 or lower) typically considered
osteoporotic [17]. One possible explanation is that the
investigators in the DANCE study may be less focused on
only bone mineral density and have taken into consideration
additionalriskfactors,suchasageandpreviousfracture,that
have been shown to be strong predictors of future fracture
[18]. Side eﬀects were signiﬁcantly associated with both early
and late discontinuation. In other studies, discontinuation
due to adverse events was 4% in the UK [19], 8% in France
[20], 6% in Europe [21], and 6% in an international clinical
trial [22].
The 3 questionnaires administered over the ﬁrst 12
months of treatment were used to identify a number of
patient-reported factors associated with discontinuation.
Diﬃculty paying for treatment and concerns outweighing
the beneﬁts were most commonly selected by the patients
as reasons for discontinuation. When the remaining patient
responses were correlated with discontinuation, side eﬀects
and ﬁnancial issues were signiﬁcantly associated, consistent
with the patient-selected reasons. Additional factors asso-
ciated with early discontinuation included concern about
improper usage, diﬃculty with the self-injection, and the
patient’s perception of the prescriber. A patient not perceiv-
ing the importance of continuing treatment was associated
with late discontinuation.
Unexpectedly, pain at the injection site was associated
with persistence rather than discontinuation. One possible
explanation is that if patients misinterpreted the intent of the
question, those who discontinued could have reported that
theynolongerexperiencedpain,becausetheywerenolonger
injecting teriparatide. On the other hand, of the 14 patients
who reported pain at the injection site “most” or “all” of the
time, only 1 of those discontinued treatment.
Also of interest is that even though “problems with
injecting” was only the fourth most common prespeciﬁed
reason provided for discontinuing treatment, signiﬁcant
trends were observed with several other questionnaire itemsJournal of Osteoporosis 5
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Figure 3: Responses to QF2 signiﬁcantly associated with late discontinuation (Cochran-Armitage trend test). Additional signiﬁcant
associations had trends similar to the questions shown and included: Over the last 6 months, have you experienced any side eﬀects with
the drug, Forteo? If yes, were they mild, moderate, or severe? Please think about the physician who is treating you with Forteo: How
knowledgeable is the physician about treatment with Forteo?
focused on injection diﬃculties. Perhaps diﬃculties with the
injection device is typically not suﬃcient as a primary reason
for discontinuation, but it was a contributing factor when
combined with other issues. such as cost or the beneﬁt-risk
balance. Although approved for marketing after the time of
this study, a newer device has been developed, evaluated in a
clinicaltrial(ClinicalTrials.govidentiﬁerNCT00577863)and
is now the standard device patients use to inject teriparatide.
The factors associated with persistence highlight the
need for better strategies to optimize teriparatide use. In
otherstudiesofinjectabletreatments,patients’self-perceived
eﬃcacy, attitudes toward the disease and the treatment,
sense of hope, perception of the physician as supportive,
as well as the interaction between the patient and the
healthcare team strongly inﬂuenced adherence [23, 24]. In a
qualitative study, Brod et al. developed a conceptual model
of persistence and adherence with injectable drugs based
on semistructured interviews of patients and physicians
who received/prescribed teriparatide [14] .T h eﬁ n a lm o d e l
reﬂected that adherence and persistence were continuing
processes that were inﬂuenced by both patient and physician
factors and that the process began before initiation of
therapy. As in this study, the physician’s level of enthusiasm
for the treatment, perceived knowledge about treatment,
resourcesdevotedtotraining,andcontinuedsupportaround
treatment were important factors. Also, as in this study,
patient’s perceptions that their illness was severe, that they
were at risk for fracture, and that treatment was likely to
be eﬀective, ﬁnancial concerns were important factors in
treatment initiation, with initial experience and side eﬀects
being important factors for short-term persistence. The
authors also identiﬁed perceived eﬃcacy playing a role in
longer-term persistence. Improved communication between
patient and physician, and, more speciﬁcally, providing
feedback based on biomarkers and highlighting the beneﬁts
of treatment rather than instilling fear about consequences
of nonadherence were also stressed in a review of optimizing
eﬃcacy with bisphosphonates treatment [25].6 Journal of Osteoporosis
The most important limitation of this study is the lack of
data on patients who were lost to followup. It was unknown
whether these patients were still on therapy, and if not, what
theirreasonswerefordiscontinuation.Second,itisuncertain
whether the DANCE population was representative of pre-
scribers and patients across the United States. For example,
many of the study investigators were considered national
experts and might have more experience and expertise
with initiating and continuing patients on teriparatide than
typical prescribers. The results presented here might not
apply to diﬀerent patient populations. Third, the length of
followup included in this report was limited to 1 year, so
longer-term issues with persistence might not be addressed.
Finally, the data were collected from patient self-reports
using surveys with only a limited number of prespeciﬁed
possible responses, which might not be a comprehensive or
accurate record of the patient’s true experience.
4. Conclusions
We observed a notably high level of persistence in this
prospective observational study, which raises the possibility
that the DANCE patients might share certain characteristics
or level of care that led to less discontinuation. Lower levels
of persistence might be expected on a national level, where
the population consists of a more diverse group of patients
and health care providers. The use of training or support
programswithinDANCEmightormightnotbegreaterthan
the general population, so we cannot conﬁdently extrapolate
these results.
If nurses and other staﬀ members are the individuals
performing the training, they could be key partners to
monitor and improve persistence. It should also be noted
that although the study was designed to be observational, the
questionnaires themselves could have had an interventional
aﬀect to improve persistence. Further studies of persistence
with teriparatide might help clarify the preliminary ﬁndings
reported here. For example, because Medicare Part D
has led to shifts in US patient populations and payment
arrangements [26], analyses with more recent data are of
substantial interest. The 2010 healthcare reform in the
United States could also change the treatment patterns again.
Finally, as teriparatide becomes commercially available in
new countries throughout the world, it will be important to
consider whether the factors associated with discontinuation
in the United States apply to other geographies.
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